Provided by Tiger Trade Technology Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

38.44
-0.2200-0.57%
Pre-market: 37.84-0.6000-1.56%04:01 EDT
Volume:1.50M
Turnover:57.74M
Market Cap:2.74B
PE:-12.35
High:39.24
Open:38.92
Low:37.82
Close:38.66
52wk High:94.90
52wk Low:20.04
Shares:71.31M
Float Shares:54.64M
Volume Ratio:1.03
T/O Rate:2.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1128
EPS(LYR):-2.3852
ROE:-20.21%
ROA:-14.95%
PB:2.02
PE(LYR):-16.12

Loading ...

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Yesterday

GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market

Options & Short Sell
·
Yesterday

Structure weakness ‘disconnected’ from underlying data, says Jefferies

TIPRANKS
·
Sep 09

Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies

Reuters
·
Sep 09

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Sep 09

Structure obesity portfolio updates ‘encouraging,’ says Clear Street

TIPRANKS
·
Sep 09

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Structure Therapeutics Releases Amylin and GLP-1 Program Presentation

Reuters
·
Sep 08

Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671

Reuters
·
Sep 08

Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Management Joins Three September Healthcare Investor Conferences

Reuters
·
Sep 03

Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $275,830.34

Reuters
·
Sep 03

Septerna to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Press Release: Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Dow Jones
·
Aug 25

Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $207,378.61

Reuters
·
Aug 20

Press Release: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 11